Patients with metastatic renal cell carcinoma (RCC) may be treated with 13 potential FDA-approved targeted therapies, of which, six are multi-tyrosine kinase inhibitors (TKIs) directed against the vascular endothelial growth factor receptor 2 (VEGFR2) [1,2,3,4,5,6,7,8,9,10,11,12]. The gene discussed is KDR; the disease is renal cell carcinoma.